Mind Performance Center

Aduhelm, once Biogen’s best hope for monetizing dementia, has had a rough ride following its controversial accelerated approval. The company abandoned commercialization attempts back in 2022, and now will settle claims they misled investors. Considering the billions that have been invested in the development of anti-amyloid drugs, the $18.9 million is “couch-cushion money” for Biogen; the much greater problem is that the repeated claims that this type of approach is the most effective treatment is misleading investors—and more importantly, patients—every day. https://www.reuters.com/legal/government/biogen-pay-189-million-settle-investors-claims-over-alzheimers-drug-2026-06-08/

Yet again, an inflammatory marker has been associated with risk for Alzheimer’s: in this case, a blood biomarker, the neutrophil (type of white blood cell associated with inflammation) to lymphocyte ratio (NLR), which is commonly associated with infection and inflammation, identified patients at risk of developing Alzheimer’s. Neutrophils are beginning to be studied for their role in Alzheimer’s, but the more relevant factor may be the underlying insults (such as infections) that caused the neutrophil increase. https://nyulangone.org/news/early-immune-changes-may-signal-increased-risk-alzheimers-dementia